Clinical Trial Detail

NCT ID NCT04458610
Title BTK Inhibitor Zanubrutinib (BGB-3111) in Combination With Rituximab for Previously Untreated Patient
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

CLL/SLL

Therapies

Rituximab + Zanubrutinib

Age Groups: adult senior

No variant requirements are available.